Surgery Partners Inc
NASDAQ:SGRY
Surgery Partners Inc
Surgery Partners Inc., a prominent player in the healthcare industry, orchestrates a robust network of surgical facilities across the United States. The company's business model is centered around operating and acquiring a variety of healthcare services, primarily focusing on short-stay surgeries through its ambulatory surgery centers, surgical hospitals, and ancillary services. Founded in 2004, Surgery Partners has grown its footprint by honing in on cost-effective, high-quality outpatient surgery, offering a compelling alternative to traditional hospital settings. This approach not only reduces healthcare costs for patients and insurers but also provides an efficient model for physicians looking to practice in specialized surgical environments.
Revenue generation for Surgery Partners is multifaceted, deriving primarily from patient service fees and strategic partnerships with healthcare providers and insurers. By maintaining a diversified portfolio that includes musculoskeletal surgeries, cardiac procedures, and other specialist operations, the company captures a broad spectrum of medical needs. Additionally, it benefits from ancillary services such as anesthesia and pathology, which are critical components of the surgical process. This integrated service offering allows Surgery Partners to maximize revenue streams while maintaining a strong presence in the outpatient surgery market. The company’s collaborative approach, working closely with physicians and leveraging strategic acquisitions, fortifies its position as a leader in the evolution toward more efficient, patient-centric healthcare delivery.
Surgery Partners Inc., a prominent player in the healthcare industry, orchestrates a robust network of surgical facilities across the United States. The company's business model is centered around operating and acquiring a variety of healthcare services, primarily focusing on short-stay surgeries through its ambulatory surgery centers, surgical hospitals, and ancillary services. Founded in 2004, Surgery Partners has grown its footprint by honing in on cost-effective, high-quality outpatient surgery, offering a compelling alternative to traditional hospital settings. This approach not only reduces healthcare costs for patients and insurers but also provides an efficient model for physicians looking to practice in specialized surgical environments.
Revenue generation for Surgery Partners is multifaceted, deriving primarily from patient service fees and strategic partnerships with healthcare providers and insurers. By maintaining a diversified portfolio that includes musculoskeletal surgeries, cardiac procedures, and other specialist operations, the company captures a broad spectrum of medical needs. Additionally, it benefits from ancillary services such as anesthesia and pathology, which are critical components of the surgical process. This integrated service offering allows Surgery Partners to maximize revenue streams while maintaining a strong presence in the outpatient surgery market. The company’s collaborative approach, working closely with physicians and leveraging strategic acquisitions, fortifies its position as a leader in the evolution toward more efficient, patient-centric healthcare delivery.
Revenue: Full year revenue of $3.3 billion, up 6.2% YoY, with Q4 revenue of $885 million (up 2.4% YoY) — full year came in at the low end of expectations.
Profitability: Full year adjusted EBITDA was $526 million (up 3.5% YoY) with a 15.9% margin (40 bps compression); Q4 adjusted EBITDA was $156.9 million (17.7% margin) and missed the company’s internal expectations.
Headwinds: The earnings shortfall was concentrated in three surgical-hospital markets driven by softer case growth, adverse payer-mix shifts toward Medicare, physician transitions and anesthesia/labor cost dynamics.
Outlook: 2026 initial guidance: net revenue $3.35B–$3.45B (3%–5% same-facility revenue growth implied) and adjusted EBITDA of at least $530 million — guidance embeds quantified headwinds.
Portfolio & capital: Deployed $182 million of acquisition capital in 2025; board authorized up to $200 million in share repurchases; portfolio optimization (select surgical-hospital divestitures / JV) is a priority to reduce leverage.
Balance sheet & liquidity: $240 million cash, $693 million revolver capacity ($933 million total available liquidity); $2.6 billion corporate debt, net leverage 4.3x (credit-agreement), 4.9x (balance-sheet).
